4 HealthTech Stocks Trending Now APRE stock, OTLK stock, DCTH stock, LUCD stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent APRE Stock Price: $6.07
Summary: Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts.
Robert Driscoll analyst at Wedbush reiterates coverage on Aprea Therapeutics, Inc. (APRE) stock in the energy sector with a Buy rating and has set APRE's stock price target at $11.
TipRanks.com reports that Aprea Therapeutics, Inc. currently has 3 analysts offering 12-month price targets on APRE and the consensus is a Buy rating with an average stock price target of $15.67. The most recent APRE stock price we have is $6.07 and we are not making any APRE forecasts at this time.
In addition, TradingView issued a sell rating for APRE over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on APRE. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on APRE, please click here >>
Outlook Therapeutics, Inc., OTLK
Recent OTLK Stock Price: $9.37
Summary: Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
Julian Harrison analyst at BTIG reiterates coverage on Outlook Therapeutics, Inc. (OTLK) stock in the energy sector with a Buy rating and has set OTLK's stock price target at $50.
TipRanks.com reports that Outlook Therapeutics, Inc. currently has 5 analysts offering 12-month price targets on OTLK and the consensus is a Buy rating with an average stock price target of $42.00. The most recent OTLK stock price we have is $9.37 and we are not making any OTLK forecasts at this time.
In addition, TradingView issued a buy rating for OTLK over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on OTLK. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on OTLK, please click here >>
Delcath Systems, Inc., DCTH
Recent DCTH Stock Price: $5.09
Summary: Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.
Swayampakula Ramakanth analyst at H.C. Wainwright reiterates coverage on Delcath Systems, Inc. (DCTH) stock in the energy sector with a Buy rating and has set DCTH's stock price target at $20.
TipRanks.com reports that Delcath Systems, Inc. currently has 4 analysts offering 12-month price targets on DCTH and the consensus is a Buy rating with an average stock price target of $17.50. The most recent DCTH stock price we have is $5.09 and we are not making any DCTH forecasts at this time.
In addition, TradingView issued a buy rating for DCTH over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DCTH. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DCTH, please click here >>
Lucid Diagnostics Inc., LUCD
Recent LUCD Stock Price: $0.99
Summary: Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.
Michael Matson analyst at Needham reiterates coverage on Lucid Diagnostics Inc. (LUCD) stock in the energy sector with a Buy rating and has set LUCD's stock price target at $2.5.
TipRanks.com reports that Lucid Diagnostics Inc. currently has 5 analysts offering 12-month price targets on LUCD and the consensus is a Buy rating with an average stock price target of $4.20. The most recent LUCD stock price we have is $0.99 and we are not making any LUCD forecasts at this time.
In addition, TradingView issued a sell rating for LUCD over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LUCD. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LUCD, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================